Showing results (1-10 of 592) with videos related to
Sort By:
Pageof 60
Cardiovascular & Hematological Disorders Drug Targets|January 1, 2010
Clopidogrel-proton pump inhibitor interaction: a primer for cliniciansChristopher Allen, Steven P Dunn, Tracy E Macaulay, et al.Cardiovascular & Hematological Agents in Medicinal Chemistry|October 26, 2011
Drug-drug interactions associated with antiplatelet therapySteven P Dunn, Tracy E MacaulayJournal of Pharmacy Practice|August 16, 2014
Angioedema related to Angiotensin inhibitorsStephanie E Knecht, Steven P Dunn, Tracy E MacaulayThe Annals of Pharmacotherapy|March 24, 2011
The role of angiotensin receptor blockers in patients with angiotensin-converting enzyme inhibitor-induced angioedemaCraig James Beavers, Steven P Dunn, Tracy E MacaulayCardiovascular & Hematological Agents in Medicinal Chemistry|May 30, 2017
Polypharmacy in Cardiovascular Medicine: Problems and Promises!Mehran Abolbashari, Tracy E Macaulay, Thomas F Whayne, et al.Expert Opinion on Pharmacotherapy|March 24, 2010
Thrombin receptor antagonism -the potential of antiplatelet medication SCH 530348Tracy E Macaulay, Christopher Allen, Khaled M ZiadaAnnals of Internal Medicine|February 2, 2026
In AF with drug-eluting stent for ≥1 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 yDebabrata Mukherjee, Annals of Internal Medicine|August 18, 2020
After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleedingDebabrata MukherjeeAnnals of Internal Medicine|September 4, 2023
In HF, with or without PAD, dapagliflozin reduced a composite of worsening HF or CV death and did not increase amputationsDebabrata MukherjeeBiochemical Pharmacology|March 26, 2002
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular eventsDebabrata MukherjeePageof 60